Zydus launches cheapest remdesivir at Rs 2,800 per 100 mg vial in India

Earlier, in June 2020, Zydus Cadila had entered into a non-exclusive agreement with Gilead Sciences Inc., to manufacture and sell Remdesivir
Pharma major Cadila Healthcare (Zydus Cadila) on Thursday announced launch of what is so far India's cheapest remdesivir brand - Remdac at Rs 2800 per 100 mg lyophilized injection vial. 

The will be made available across India through the group’s strong distribution chain reaching out to government and private hospitals treating Covid patients.

According to Sharvil Patel, managing director of Cadila Healthcare, as the most affordable remdesivir brand, Remdac will enable patients ot have access to the critical drug in treatment of Covid-19. 

"Through the course of this pandemic, our efforts have been focussed on supporting people in this healthcare crisis, whether it is through developing vaccines, ramping up production and distribution of critical drugs and therapies, making diagnostic tests available or exploring new treatment options,"” Patel added.

Earlier, in June 2020, Zydus Cadila had entered into a non-exclusive agreement with Gilead Sciences Inc., to manufacture and sell Remdesivir, the investigational drug, which has been issued an Emergency Use Authorization by the US Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of Covid 19. The active pharmaceutical ingredient (API) for the drug has been developed and manufactured at the group’s API manufacturing facilities in Gujarat.

Apart from rolling out Remdac, Zydus group has been engaged in other efforts to the fight the pandemic with vaccines, therapeutics and diagnostics.  On one hand, the group had ramped up production of HCQ and Dexamethasone when required and is also conducting clinical trials with Pegylated Interferon Alpha 2b and Desidustat for the treatment and management of Covid 19. Nearly 300,000 Covid Kavach Elisa diagnostic tests have been supplied for surveillance. 

Meanwhile, the group’s plasmid DNA vaccine ZyCoV-D is now in Phase II of the Adaptive Phase I&II clinical trials and has been one of the forerunners of vaccine development in India.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel